1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2020.08.1133
Abstract: Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: AstraZeneca; Research grant/Funding (self): Boehringer Ingelheim. A.B. El-Khoueiry: Honoraria (self), Advisory/Consultancy: CytomX Therapeutics; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Eisai; Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy:… read more here.
Keywords: research grant; advisory consultancy; self advisory; honoraria self ... See more keywords
Neoadjuvant olaparib monotherapy in primary triple negative breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz240.010
Abstract: Abstract Background Neoadjuvant treatment of triple negative breast cancer (TNBC) in general implies different chemotherapy regimens administered in sequence. PARP inhibitors like olaparib have revealed clinical benefit in TNBC harboring BRCA germline mutations, but were… read more here.
Keywords: grant funding; research grant; honoraria self; honoraria ... See more keywords
Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz240.012
Abstract: Abstract Background DD adjuvant CT improves disease free survival (DFS) and overall survival (OS) in high-risk, hormone receptor positive BC. Luminal A and luminal B subtypes have different sensitivity to (neo)adjuvant chemotherapy; however, their role… read more here.
Keywords: luminal subtypes; honoraria self; luminal like; advisory consultancy ... See more keywords
Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz242
Abstract: Abstract Background T-DM1 is indicated for the treatment of HER2+ metastatic BC previously treated with trastuzumab and a taxane, separately or in combination. Atezo is an anti-PD-L1 antibody that inhibits PD-L1 binding to PD-1 and… read more here.
Keywords: dm1; pbo; self advisory; honoraria self ... See more keywords
Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz242.046
Abstract: Abstract Background Both pertuzumab and T-DM1 improved overall survival (OS) of HER2+ metastatic breast cancer (MBC) in clinical trials. Little is known about their activity outside of clinical trials and when administered sequentially or after… read more here.
Keywords: accommodation expenses; honoraria self; advisory consultancy; travel accommodation ... See more keywords
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz244.009
Abstract: Abstract Background MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in preclinical RAS mutant cancer models. BCL-XL is an anti-apoptotic BCL2 family protein… read more here.
Keywords: bcl mek; treatment; inhibition; ras mutant ... See more keywords
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.030
Abstract: Abstract Background The AVANT study did not demonstrate disease-free survival (DFS) benefit of the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III resected CC and suggested a potential detrimental effect on overall survival (OS)… read more here.
Keywords: research grant; grant funding; honoraria self; advisory consultancy ... See more keywords
POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.062
Abstract: Abstract Background Biomarkers associated to antiangiogiogenic agents in metastatic colorectal cancer (mCRC) have not yet been validated Here we present the efficacy and safety results of FOLFIRI and aflibercept in second line therapy for mCRC… read more here.
Keywords: honoraria institution; honoraria self; advisory consultancy;
JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.096
Abstract: Abstract Background Combination treatment of FTD/TPI plus BEV in the C-TASK FORCE showed a promising activity in pts with mCRC refractory or intolerant to standard chemotherapies; however, due to the small sample size, it remains… read more here.
Keywords: grant funding; research grant; honoraria self; honoraria ... See more keywords
Molecular subtypes of metastatic (met) gastric cancer (GC) (MoTriGastric): New biomarkers closer to the clinics
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz247.149
Abstract: Abstract Background Clinical and molecular heterogeneity of GC is broadly recognized. Three molecular classifications based on sample profiling from resected early-stage tumours have been proposed. Apart from microsatellite instability (MSI) subgroup, they provide conflicting results… read more here.
Keywords: research grant; honoraria speaking; honoraria self; advisory consultancy ... See more keywords
Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz248.025
Abstract: Abstract Background Three recent RCT (Spartan, Prosper and Aramis) have demonstrated improved metastasis-free survival with new ARi Apalutamide (A), Enzalutamide (E) and Darolutamide (D), respectively, vs placebo (pl) in nmCRPC. We conducted a meta-analysis of… read more here.
Keywords: travel accommodation; honoraria self; meta analysis; advisory consultancy ... See more keywords